PTPI_OUT_1 [2025-03-26 04:34:28 -0400] 2153 Bytes | 564 tokens | Cum: 564 tkns (7.05% of 8k)
==========================================================================

Listen up, partner—it's 4:34:27 AM on Wed Mar 26, 2025 -0400, and I’m revved up about Petros Pharmaceuticals (PTPI), climbing from 0.0578 to 0.0771. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for Petros Pharmaceuticals:

C1 - Mar-20-25 09:15AM - Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications
C2 - Feb-25-25 09:20AM - Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study
C3 - Feb-18-25 09:25AM - Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants
C4 - Jan-07-25 09:15AM - Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules
C5 - Dec-19-24 09:15AM - Petros Pharmaceuticals Featured in 'New Era of Healthcare, AI, Data and Consumer Empowerment'
C6 - Dec-17-24 09:00AM - Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually
C7 - Oct-19-24 05:28PM - Petros Pharmaceuticals Amends Presidents Employment Terms
C8 - Sep-11-24 09:15AM - Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Petros Pharmaceuticals (PTPI)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PTPI_OUT_3 [2025-03-26 04:34:31 -0400] 1039 Bytes | 245 tokens | Cum: 811 tkns (10.14% of 8k)
==========================================================================

Showing C2 (chunk 1 of 10): C2:
**Petros Pharmaceuticals' Proprietary Technology Demonstrates Positive Data in Pivotal Study**
Date: Feb-25-25 09:20AM
Source: (ACCESS Newswire)
URL: https://finance.yahoo.com/news/petros-pharmaceuticals-proprietary-technology-demonstrates-142000649.html

Proprietary technology utilizing AI and big data integrations to enable Rx to OTC switch candidates across multiple indications

NEW YORK, NY /ACCESS Newswire/ February 25, 2025 /Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, announces top-line results of its expanded Application Comprehension ("App Comp") study, which determines consumer comprehension of its unique messaging within its proprietary Technology. In the study, the Company's technology facilitated consumer's understanding of d

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PTPI_OUT_5 [2025-03-26 04:34:33 -0400] 1039 Bytes | 229 tokens | Cum: 1042 tkns (13.03% of 8k)
==========================================================================

Showing C2 (chunk 2 of 10): esignated critical objectives (with a success threshold of 90% or 85% based on clinical significance of the objective). There were an additional 17 important objectives designated without a lower bound (LB) threshold. The 400 patient-consumer study with 31 objectives in total successfully achieved 4 of 5 among the most critical objectives, 9 of 9 of the next tier critical objectives, and all 17 important objectives exceeding an 84% LB threshold.

Fady Boctor, Petros' President and Chief Commercial Officer, commented, "This study supports our belief that, through this emerging technology, we can expand access of current Rx medications to OTC. The addition of AI and big data integration are key components to help optimize this access, and we are diligently creating a scalable Software as a Medical Device (SaMD) approach, which we believe can significantly enhance the emerging self-care mar

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PTPI_OUT_7 [2025-03-26 04:34:35 -0400] 1009 Bytes | 281 tokens | Cum: 1325 tkns (16.56% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-20T13:35:53Z - Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across ...
A2 - 2025-03-20T13:26:00Z - Petros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Partner with Renowned Big Data Provider to E...
A3 - 2025-03-20T13:20:49Z - Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across ...
A4 - 2025-03-20T13:20:49Z - Petros Pharmaceuticals, (PTPI) to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch...
A5 - 2025-02-25T14:27:14Z - Petros reports success in AI-assisted Rx-to-OTC study By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PTPI_OUT_9 [2025-03-26 04:34:36 -0400] 1038 Bytes | 239 tokens | Cum: 1566 tkns (19.57% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Petros Pharmaceuticals to Partner with Renowned Big Data Provider to Enable Rx-to-OTC Switch Across Multiple Indications**Date: 2025-03-20Source: {'uri': 'wallstreet-online.de', 'dataType': 'news', 'title': 'wallstreet:online'}URL: https://www.wallstreet-online.de/nachricht/19136206-petros-pharmaceuticals-to-partner-with-renowned-big-data-provider-to-enable-rx-to-otc-switch-across-multiple-indicationsCompany to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter NEW YORK, NY / ACCESS Newswire / March 20, ...

Company to integrate industry leading big data technology solutions into its AI-driven platform to expand capabilities in identifying eligible patients to receive formerly Rx medications over the counter

NEW YORK, NY / ACCESS Newswire /

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PTPI_OUT_11 [2025-03-26 04:34:42 -0400] 939 Bytes | 194 tokens | Cum: 1762 tkns (22.02% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): March 20, 2025 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announces a collaboration with renowned Big Data and analytics leader to enhance the development of its proprietary technology solutions designed to facilitate Rx-to-OTC switches for pharmaceutical products. The collaboration will incorporate an automated credentialing solution to help improve the Company's identity verification system, which also encompasses an AI component. The Company believes the collaboration will significantly enhance the capabilities as it develops its Software-as-a-Medical Device (SaMD) concept, which is designed to serve the emerging self-care market.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PTPI_OUT_13 [2025-03-26 04:34:44 -0400] 1030 Bytes | 313 tokens | Cum: 2179 tkns (27.24% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-04-02T17:23:42Z - Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B2 - 2024-01-30T18:18:27Z - Why UPS Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B3 - 2024-01-30T12:52:14Z - Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
B4 - 2023-12-13T12:55:44Z - Why ReShape Lifesciences Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
B5 - 2023-10-04T12:03:28Z - Why Brooge Energy Shares Are Trading Higher By Around 24%; Here Are 20 Stocks Moving Premarket
B6 - 2023-07-13T12:12:35Z - Why Senmiao Technology Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PTPI_OUT_15 [2025-03-26 04:34:51 -0400] 1042 Bytes | 290 tokens | Cum: 2471 tkns (30.89% of 8k)
==========================================================================

Showing B1 (chunk 1 of 3): B1:
**Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/24/04/38053729/why-stryve-foods-shares-are-trading-lower-by-around-25-here-are-other-stocks-moving-in-tuesdays-midShares of Stryve Foods, Inc. (NASDAQ: SNAX) fell sharply during Tuesday’s session following a fourth-quarter revenue miss.
Stryve Foods posted adjusted loss of $1.90 per share, versus market estimates for a loss of $1.96 per share. The company’s sales came in at $2.887 million versus expectations of $5.009 million, according to data from Benzinga Pro.
Stryve Foods shares dipped 25.2% to $1.0965 on Tuesday.
Here are some other stocks moving in today's mid-day session.
Gainers

VivoPower International PLC (NASDAQ: VVPR) shares surged 315% to $6.10 after the company's Tembo subsidiary

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PTPI_OUT_17 [2025-03-26 04:34:53 -0400] 1076 Bytes | 302 tokens | Cum: 2874 tkns (35.93% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-21 8-K Item 1.01 Entry into a Material Definitive Agrmt

On February 17, 2025, Petros Pharmaceuticals, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agrmt) with certain institutional and accredited investors (collectively, the Investors) for the ...

S7 - 2025-01-24 8-K Item 1.01 Entry into a Material Definitive Agrmt

As previously disclosed, on July 13, 2023, Petros Pharmaceuticals, Inc. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) with certain accredited investors (the Investors) pursuant to which i...

S8 - 2024-11-13 10-Q PART IFIN INFO

ITEM 1. UNAUDITED FIN STATEMENTS.

PETROS PHARMACEUTICALS, INC.

COND CONS BAL SHEETS

September 30,

December 31,

(Unaudited)

Assets

Curr assets:

Cash

$

3,894,685

$

13,336,975

A/R, net

1,948,...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PTPI_OUT_19 [2025-03-26 04:34:58 -0400] 1038 Bytes | 267 tokens | Cum: 3143 tkns (39.29% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 1.01 Entry into a Material Definitive Agreement

On February 17, 2025, Petros Pharmaceuticals, Inc. (the Company) entered into a securities purchase agreement (the Purchase Agreement) with certain institutional and accredited investors (collectively, the Investors) for the issuance and sale, in a best efforts public offering (the Offering), of (i) 13,950,012 units (the Units), each Unit consisting of one share (the Shares) of the Companys common stock, par value $0.0001 per share (the Common Stock), one Series A Warrant (the Series A Warrants) to purchase 0.25 share of Common Stock (the Series A Warrant Shares) and one Series B Warrant (the Series B Warrants, and together with the Series A Warrants, the Warrants) to purchase one shares of Common Stock (the Series B Warrant Shares and, together with the Series A Warrant Shares, the Warrant Shares) and (ii) 26,049,988 pre-funded

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PTPI_OUT_21 [2025-03-26 04:35:05 -0400] 1038 Bytes | 250 tokens | Cum: 3395 tkns (42.44% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): units (the Pre-Funded Units), each Pre-Funded Unit consisting of one pre-funded warrant (the Pre-Funded Warrants) to purchase one share of Common Stock (the Pre-Funded Warrant Shares), one Series A Warrant and one Series B Warrant. The public offering price was $0.24 per Unit and $0.2399 per Pre-Funded Unit. The Offering closed on February 19, 2025. The exercise price of each of the Series A Warrants and the Series B Warrants is $0.48 per share of Common Stock.

The exercisability of the Warrants will be available only upon receipt of such stockholder approval as may be required by the applicable rules and regulations of the Nasdaq Capital Market LLC, including, but not limited to, with respect to (i) the issuance of all of the shares of Common Stock issuable upon exercise the Warrants in accordance with their terms (including adjustment provisions set forth therein), and (ii) to consent

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PTPI_OUT_23 [2025-03-26 04:35:22 -0400] 4931 Bytes | 1416 tokens | Cum: 4942 tkns (61.78% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+----------------------+------------------------+------------------------+-----------------------+
| Volume: 17,604,087 | SMA50: -69.41% | Market Cap: 1.73M | Option/Short: No / Yes | Sales past 5Y: -20.76% | Sales Surprise: 0.01% |
+--------------------+-----------------------+----------------------+------------------------+------------------------+-----------------------+
| Avg Volume: 7.38M | SMA200: -81.95% | Shs Outstand: 29.93M | Short Float: 1.43% | Employees: 21 | EPS Surprise: 0.00% |
+--------------------+-----------------------+----------------------+------------------------+------------------------+-----------------------+
| Rel Volume: 2.39 | Perf Week: -20.82% | Shs Float: 24.49M | Short Ratio: 0.05 | Debt/Eq: 2.32 | P/E: - |
+--------------------+-----------------------+----------------------+------------------------+------------------------+-----------------------+
| RSI (14): 26.98 | Perf Month: -50.81% | Inst Own: 3.25% | Short Interest: 0.35M | Sales Y/Y TTM: - | Earnings: - |
+--------------------+-----------------------+----------------------+------------------------+------------------------+-----------------------+
| ATR (14): 0.02 | Perf Quarter: -81.48% | Insider Own: 18.16% | Beta: 2.08 | ROE: - | |
+--------------------+-----------------------+----------------------+------------------------+------------------------+-----------------------+
| SMA20: -33.43% | Index: - | Insider Trans: 0.00% | Sales Q/Q: -20.94% | ROI: - | |
+--------------------+-----------------------+----------------------+------------------------+------------------------+-----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: Petros Pharmaceuticals, Inc. (PTPI) by Bernstein Bruce (Unknown Title) on 2025-02-19
- Common Stock: 300000 shares at $0 (D)

Inside Trans: Petros Pharmaceuticals, Inc. (PTPI) by Boctor Fady (See Remarks) on 2025-02-19
- Common Stock: 450000 shares at $0 (D)

Inside Trans: Petros Pharmaceuticals, Inc. (PTPI) by Silverman Joshua (Unknown Title) on 2025-02-19
- Common Stock: 1000000 shares at $0 (D)

Inside Trans: Petros Pharmaceuticals, Inc. (PTPI) by Arnold Mitchell (See Remarks) on 2025-02-19
- Common Stock: 150000 shares at $0 (D)

Inside Trans: Petros Pharmaceuticals, Inc. (PTPI) by WALKER WAYNE REMELL (Unknown Title) on 2025-02-19
- Common Stock: 150000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 4022392.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -4727200.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.0578
Average Volume: 10882870.23
30-Day High: 0.1175
30-Day Low: 0.0578

[Detailed Financials: Q3 2024]
- Total Assets: $20,693,630.0
- Total Liabilities: $17,576,521.0
- Total Equity: $3,115,711.0
- Current Assets: $10,724,480.0
- Current Liabilities: $12,562,104.0

[Income Statement: Q3 2024]
- Revenue: $1,576,366.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.53

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-9,442,290.0

[Detailed Financials: Q2 2024]
- Total Assets: $25,169,274.0
- Total Liabilities: $15,983,229.0
- Total Equity: $8,070,283.0
- Current Assets: $13,979,045.0
- Current Liabilities: $9,976,345.0

[Income Statement: Q2 2024]
- Revenue: $1,421,471.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PTPI_OUT_25 [2025-03-26 04:35:24 -0400] 676 Bytes | 167 tokens | Cum: 5357 tkns (66.96% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PTPI_IN_27 [2025-03-26 04:35:25 -0400] 126 Bytes | 29 tokens | Cum: 5414 tkns (67.67% of 8k)
==========================================================================

====================================
[2025-03-26 01:35:25] # Analysis Completed
Elapsed Time: 58.76 seconds